Navigation Links
Pipeline for New Obesity Therapies is Focus of New Report
Date:1/7/2008

SCOTTSDALE, Ariz., Jan. 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published "Thought Leader Insight & Analysis: Obesity," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for obesity therapies.

By many measures, obesity in the Western World is reaching epidemic proportions. Unlike diabetes and cardiovascular disease, however, the medical justification for treating obesity is not directly tied to hard outcomes, and the pharmacoeconomics do not yet motivate third-party payers to broadly reimburse for pharmacotherapies.

Against this backdrop, seven internationally-recognized obesity experts comment on centrally acting, peripheral and non-systemic approaches to weight reduction, including:

-- Rimonabant, comparing next-generation CB-1 antagonists and inverse

agonists in terms of efficacy and propensity to cause depression and

other psychiatric disorders,

-- Other centrally acting agents, alone and in combination,

-- The pure peripheral drugs, using exenatide as the base for comparison

and positioning other GLP-1 agonists against its weaknesses,

-- Leptin, PYY, mitochondrial metabolism and other approaches to

"inefficient caloric consumption",

-- And non-systemic mechanisms, including follow up approaches after

orlistat, and novel approaches such as SGLT inhibition.

Key drugs discussed in this report include: Acomplia (rimonabant; Sanofi-Aventis), taranabant (MK-0364; Merck), CP-945598 (Pfizer), SLV 319 (BMS-646256; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-1625 (Sanofi-Aventis), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), Contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byetta (exenatide; Amylin/Lilly), exenatide LAR (Lilly/Amylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin; Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY 3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-7871; UC Riverside / Chinese Academy of Science); Substituted quinoxalines (Novo Nordisk/ Pfizer), PYY 3-36 (Nastech), CYT009-GhrQb (Cytos), Xenical / alli (orlistat; Roche / GSK), cetilistat (Alizyme/ Takeda), SGLT inhibitors.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
2. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
3. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. China Holdings, Inc. Announces Its 3rd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 150 MW in Biomass Energy Pipeline
6. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
7. Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Councils Ninth Annual MASS Opportunities Investment Conference
8. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
9. Clinical studies in the pipeline: the therapies of tomorrow in trials today
10. Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the ... , As Winston Churchill said, “Those who don’t learn from history are ... what to expect when they come knocking this year. But that takes time. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... CULVER CITY, California (PRWEB) , ... February 12, 2016 , ... ... to announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco ... and healthy way to stay hydrated before the big event. The invitation-only gifting suite, ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... 12, 2016 , ... Every winter, someone is killed, injured or loses a ... Burn Center, part of the Allegheny Health Network, has partnered with Etna Volunteer ... Heaters Need Space” campaign. , “Space Heaters Need Space” aims to bring ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
(Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, ... conference call and webcast to discuss its financial results ... 2015, on Thursday, February 25, 2016 at 8:00 a.m. ... prior to the conference call and webcast.  On the ... financial results, highlights from the fourth quarter and business ...
(Date:2/12/2016)... ALISO VIEJO , Kalifornien, 12. Februar 2016 ... es mit der Aufnahme von Patienten für eine ... Embolisation von Aneurysmen („WEB") speziell für die Behandlung ... Laurent Spelle , MD, Leiter der Neuroradiologie an ... , Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ...
Breaking Medicine Technology: